| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2014 | DE102012013482A1 Zusammensetzung zur Förderung der Wiederherstellung von verletztem Körpergewebe Composition for promoting the recovery of injured body tissue |
| 01/09/2014 | CA2878413A1 Therapeutic bisphosphonates |
| 01/09/2014 | CA2878402A1 Andrographis paniculata compositions and methods for treatment of addictions |
| 01/09/2014 | CA2878376A1 Transdermally absorbable preparation containing rotigotine |
| 01/09/2014 | CA2878346A1 New indene derivatives, their preparation and use as medicaments |
| 01/09/2014 | CA2878339A1 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments |
| 01/09/2014 | CA2878319A1 Polymorphs of n-[(r)-1-[(s)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl- ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride |
| 01/09/2014 | CA2878292A1 Potentiation of antibiotic treatment with a protein-lipid complex |
| 01/09/2014 | CA2878152A1 Methods of treating arthritis |
| 01/09/2014 | CA2878123A1 Pharmaceutical administration forms comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
| 01/09/2014 | CA2878027A1 Manufacture of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid |
| 01/09/2014 | CA2878000A1 Benzodioxole derivative and preparation method and use thereof |
| 01/09/2014 | CA2877999A1 Heterocyclic modulators of lipid synthesis |
| 01/09/2014 | CA2877848A1 Therapeutic method and medicament for htlv-1 associated myelopathy (ham) |
| 01/09/2014 | CA2877805A1 Use of an inhibitor of irs-1 for treating skin disorders |
| 01/09/2014 | CA2877766A1 Quercetin-3-glucoside and uses thereof |
| 01/09/2014 | CA2877644A1 Oligonucleotide for the treatment of muscular dystrophy patients |
| 01/09/2014 | CA2877603A1 Novel cholecystokinin receptor ligands |
| 01/09/2014 | CA2877541A1 Ticagrelor adducts with divalent metal salts |
| 01/09/2014 | CA2877393A1 Compositions comprising sulforaphane or a sulforaphane precursor and ursolic acid |
| 01/09/2014 | CA2877356A1 Compositions comprising a sulforaphane or a sulforaphane precursor and milk thistle extract or powder |
| 01/09/2014 | CA2877338A1 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder |
| 01/09/2014 | CA2877335A1 Method of treating retroviral infections and related dosage regimes |
| 01/09/2014 | CA2877329A1 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium |
| 01/09/2014 | CA2877183A1 Abuse deterrent pharmaceutical compositions for controlled release |
| 01/09/2014 | CA2877005A1 Inhibitors of hepatitis c virus |
| 01/09/2014 | CA2876995A1 Selective pi3k delta inhibitors |
| 01/09/2014 | CA2876883A1 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
| 01/09/2014 | CA2876808A1 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| 01/09/2014 | CA2876689A1 Substituted tricyclic compounds as fgfr inhibitors |
| 01/09/2014 | CA2876443A1 Novel adamantyl derivatives as cannabinoid receptor 2 agonists |
| 01/09/2014 | CA2874815A1 Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof |
| 01/08/2014 | EP2682468A2 Gene silencing of the brother of the regulator of imprinted sites (BORIS) |
| 01/08/2014 | EP2682467A1 Use of an inhibitor of IRS-1 for treating skin disorders |
| 01/08/2014 | EP2682462A1 (nucleic acid)-polysaccharide complex |
| 01/08/2014 | EP2682399A1 Novel macrolide intermediate and novel production process |
| 01/08/2014 | EP2682397A1 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 01/08/2014 | EP2682395A1 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments |
| 01/08/2014 | EP2682394A1 1H-pyrazolo[3,4-b]pyridin-triazine derivatives and their use for the treatment or the prevention of cardiovascular diseases |
| 01/08/2014 | EP2682393A1 Inhibitors of HCV NS5A comprising a bicyclic core. |
| 01/08/2014 | EP2682392A2 Pyrazole derivatives, preparation method thereof, and composition for preventing and treating osteoporosis containing same |
| 01/08/2014 | EP2682391A1 Indene derivatives, their preparation and use as medicaments |
| 01/08/2014 | EP2682390A1 2-aminothiazole derivative, preparation method, and use |
| 01/08/2014 | EP2682389A1 Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter |
| 01/08/2014 | EP2682388A1 Novel polymorphic forms of perindopril (L)-arginine and process for the preparation thereof |
| 01/08/2014 | EP2682387A2 C7-fluoro substituted tetracycline compounds |
| 01/08/2014 | EP2682386A1 Novel vitamin d receptor modulator with partial agonist activity |
| 01/08/2014 | EP2682384A1 Auto-magnetic metal salen complex compound |
| 01/08/2014 | EP2682381A2 Spirocyclic cyclopropanoic amino acids - analogues of gamma-aminobutyric acid, with limited conformational mobility, and drugs on the basis thereof |
| 01/08/2014 | EP2682130A1 Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| 01/08/2014 | EP2682129A2 Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous |
| 01/08/2014 | EP2682122A1 Growth hormone secretion promoter |
| 01/08/2014 | EP2682121A1 Pharmaceutical use of aminothiazole myd88 specificity inhibitor |
| 01/08/2014 | EP2682120A1 Stable laquinimod preparations |
| 01/08/2014 | EP2682119A1 Aromatic N-heterocycle derivatives for use as medicine |
| 01/08/2014 | EP2682118A1 Psoralen derivatives for the treatment of heart failure and heart hypertophy |
| 01/08/2014 | EP2682117A1 The use of L-butylphthalide in the manufacturing of medicines for the prevention and treatment of cerebral ischemia disease |
| 01/08/2014 | EP2682116A1 Metabolic syndrome ameliorating agent |
| 01/08/2014 | EP2682115A1 Internal parasiticide |
| 01/08/2014 | EP2682114A1 Milnacipran for the long-term treatment of fibromyalgia syndrome |
| 01/08/2014 | EP2682112A1 Combined capsule formulations of flurbiprofen and famotidine |
| 01/08/2014 | EP2682111A1 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
| 01/08/2014 | EP2682108A2 Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component |
| 01/08/2014 | EP2682105A1 Orally-disintegrating formulations of dexketoprofen |
| 01/08/2014 | EP2682104A1 Orally-disintegrating formulations of dexketoprofen |
| 01/08/2014 | EP2682103A2 Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol |
| 01/08/2014 | EP2682102A2 Inhalation Compositions Comprising Corticosteroid and Sorbitol |
| 01/08/2014 | EP2682101A2 Inhalation Compositions Comprising Glucose Anhydrous |
| 01/08/2014 | EP2682100A2 Inhalation Compositions Comprising Muscarinic Receptor Antagonist |
| 01/08/2014 | EP2682099A1 Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists |
| 01/08/2014 | EP2682098A2 Inhalation Compositions |
| 01/08/2014 | EP2682097A2 Dry Powder Inhalers Comprising A Carrier Other Than Lactose |
| 01/08/2014 | EP2682095A1 Family of polyamine arylethylamide compounds, and their cosmetic or dermocosmetic use |
| 01/08/2014 | EP2682005A1 A dietary supplement composition |
| 01/08/2014 | EP2681996A1 Biocidal compositions |
| 01/08/2014 | EP2681559A1 Peptide-lipid constructs and their use in a fc-function assay |
| 01/08/2014 | EP2681336A2 Enhanced biodistribution of oligomers |
| 01/08/2014 | EP2681227A1 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
| 01/08/2014 | EP2681221A1 Tricyclic inhibitors of kinases |
| 01/08/2014 | EP2681219A1 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| 01/08/2014 | EP2681218A1 IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| 01/08/2014 | EP2681216A2 Substituted 6,5-fused bicyclic heteroaryl compounds |
| 01/08/2014 | EP2681215A1 Serine/threonine kinase inhibitors |
| 01/08/2014 | EP2681214A1 Bridged piperidine derivatives |
| 01/08/2014 | EP2681213A1 Anhydrous crystalline form of tiotropium bromide |
| 01/08/2014 | EP2681212A1 Crystalline compound comprising tiotropium bromide |
| 01/08/2014 | EP2681211A1 Crystalline compound comprising tiotropium bromide |
| 01/08/2014 | EP2681210A1 1,4 thiazepines/sulfones as bace1 and/or bace2 inhibitors |
| 01/08/2014 | EP2681209A1 Compounds and methods for the treatment of pain and other disorders |
| 01/08/2014 | EP2681208A1 Antimicrobial/adjuvant compounds and methods |
| 01/08/2014 | EP2681206A1 Mst1 kinase inhibitors and methods of their use |
| 01/08/2014 | EP2681205A1 Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| 01/08/2014 | EP2681203A1 NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES |
| 01/08/2014 | EP2681200A1 Benzimidazole inhibitors of the sodium channel |
| 01/08/2014 | EP2681198A1 Novel small-molecules as therapeutics |
| 01/08/2014 | EP2681197A1 Tetrasubstituted cyclohexyl compounds as kinase inhibitors |
| 01/08/2014 | EP2681195A1 Novel kinase inhibitors |
| 01/08/2014 | EP2681194A1 3-amino-pyridines as gpbar1 agonists |
| 01/08/2014 | EP2681193A1 Pharmaceutically active disubstituted pyridine derivatives |
| 01/08/2014 | EP2681190A1 Pyrrolidine derivatives as selective glycosidase inhibitors and uses thereof |